BUZZ-Bio-Rad Laboratories down after Q4 sales miss

Shares of California-based diagnostic firm Bio-Rad BIO.N down 8.25% at $281.10

Co reports Q4 sales of $667.5 million, missing analysts' estimate of $679.3 million, according to data compiled by LSEG

Expects 2025 revenue growth of about 1.5% to 3.5% and operating margin of ~13% to 13.5%

The forecast is mixed, as core growth bracketed expectations, but margins disappointed - Jefferies

Co says will lay off about 5% of its workforce as a part of its restructuring plan - filing

Adds will incur between about $45 million and $50 million in costs

It reported Q4. adj profit of $2.9 vs est. $2.87

In the last 12 months, the stock has fallen ~15%